期刊
CURRENT NEUROPHARMACOLOGY
卷 12, 期 3, 页码 273-280出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X1203140511160832
关键词
Cognition; immunology; inflammation; schizophrenia
资金
- Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (Fapemig, Brazil)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)
Objective: Recent evidence has associated immune and inflammatory changes to cognitive performance in many diseases, including schizophrenia. Since this is a new research field where concepts are not yet solid and new questions and hypothesis are still arising, the present study aimed at summarizing the available clinical data associating schizophrenia, cognition and inflammation/immune function. Methods: A systematic review of the literature was made by searching the following terms in Medline: schizophrenia or psychosis or psychotic AND inflamm* or immun* or cytokine or IL-* or TNF-* or kynureni* or KYNA, AND cognit* or attention or memory or executive function. Results: Seventy five papers were identified using the selected terms, and seven papers were included in the review. Papers excluded focused mainly on basic research or other neuropsychiatric disorders. Conclusions: Recent findings link inflammatory markers to cognition in schizophrenia, suggesting that inflammation is associated with worst cognitive performance. Microglial activation, monoaminergic imbalance, brain abnormalities and the kynurenine pathway are possible mechanisms underlying cognitive impairment in schizophrenia. Clinical trials with addition of immunomodulatory drugs have shown promising results, opening new windows to tackle cognition in schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据